Abstract:Non-alcoholic fatty liver disease (NAFLD) is currently the most common liver disease worldwide, both in adults and children. It is characterized by an aberrant lipid storage in hepatocytes, named hepatic steatosis. Simple steatosis remains a benign process in most affected patients, while some of them develop superimposed necroinflammatory activity with a non-specific inflammatory infiltrate and a progression to non-alcoholic steatohepatitis with or without fibrosis. Deep similarity and interconnections between innate immune cells and those of liver parenchyma have been highlighted and showed to play a key role in the development of chronic liver disease. The liver can be considered as an "immune organ" because it hosts non-lymphoid cells, such as macrophage Kupffer cells, stellate and dendritic cells, and lymphoid cells. Many of these cells are components of the classic innate immune system, enabling the liver to play a major role in response to pathogens. Although the liver provides a "tolerogenic" environment, aberrant activation of innate immune signaling may trigger "harmful" inflammation that contributes to tissue injury, fibrosis, and carcinogenesis. Pathogen recognition receptors, such as toll-like receptors and nucleotide oligomerization domain-like receptors, are responsible for the recognition of immunogenic signals, and represent the major conduit for sensing hepatic and non-hepatic noxious stimuli. A pivotal role in liver inflammation is also played by cytokines, which can initiate or have a part in immune response, triggering hepatic intracellular signaling pathways. The sum of inflammatory signals and deranged substrate handling induce most of the metabolic alteration traits: insulin resistance, obesity, diabetes, hyperlipidemia, and their compounded combined effects. In this review, we discuss the relevant role of innate immune cell activation in relation to NAFLD, the metabolic complications associated to this pathology, and the possible pharmacological tools.

Role of Hepatokines in Non-alcoholic Fatty Liver Disease

Extrahepatic organs in the development of non-alcoholic fatty liver disease in liver transplant patients

Hepatokines: unveiling the molecular and cellular mechanisms connecting hepatic tissue to insulin resistance and inflammation

Role of hepatic lipid species in the progression of nonalcoholic fatty liver disease

The role of novel adipokines and adipose-derived extracellular vesicles (ADEVs): Connections and interactions in liver diseases

Roles of Abnormal Lipid Metabolism in Pathogenesis of Non-Alcoholic Fatty Liver Disease

Shedding light on non-alcoholic fatty liver disease: Pathogenesis, molecular mechanisms, models, and emerging therapeutics

The liver as an endocrine organ - linking NAFLD and insulin resistance.

The Role of Innate Immune Cells in Nonalcoholic Fatty Liver Disease

Metabolic Changes of Hepatocytes in NAFLD

Role of Angiogenesis in the Pathogenesis of NAFLD

Recent Advances in Adipose Tissue Dysfunction and Its Role in the Pathogenesis of Non-Alcoholic Fatty Liver Disease

Role of Innate Immune Response in Non-Alcoholic Fatty Liver Disease: Metabolic Complications and Therapeutic Tools

Targeting hepatic macrophages for non-alcoholic fatty liver disease therapy

Lipid Disorders in NAFLD and Chronic Kidney Disease

The Role of Innate Immune Cells in Nonalcoholic Steatohepatitis

Osteokines in Nonalcoholic Fatty Liver Disease

Hepatocyte Mitochondrial Dynamics and Bioenergetics in Obesity-Related Non-Alcoholic Fatty Liver Disease

Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis

Unraveling the Role of Leptin in Liver Function and Its Relationship with Liver Diseases

The Evolving Role of Fetuin-A in Nonalcoholic Fatty Liver Disease: An Overview from Liver to the Heart